Table 1 Patients’ characteristics
Gender | ||
 Male | 56 | 60.9% |
 Female | 36 | 39.1% |
Age | 52.8 ± 11.0 |  |
 <60 | 69 | 75.0% |
 ≥ 60 | 23 | 25.0% |
Other parts of metastasisa | ||
 Y | 58 | 63.0% |
 N | 34 | 37.0% |
Abnormal tumor markers | ||
 Y | 47 | 51.1% |
 N | 45 | 48.9% |
Number | ||
 1 | 67 | 72.8% |
 2 | 9 | 9.8% |
 ≥ 3 | 16 | 17.4% |
Maximum diameter (cm) | 33.2 ± 17.1 |  |
 ≤ 3 | 48 | 52.2% |
 3–5 | 28 | 30.4% |
 ≥ 5 | 16 | 17.4% |
Location | ||
 Anterior renal vein | 43 | 46.7% |
 Posterior renal vein | 49 | 53.3% |
Previous chemotherapy | 8.6 ± 6.3 |  |
 <10 | 38 | 76.0% |
 ≥ 10 | 12 | 24.0% |
Previous radiotherapyb | ||
 Y | 8 | 8.7% |
 N | 84 | 91.3% |
Primary tumor | ||
 Hepatic cancer | 33 | 35.9% |
 Ovarian cancer | 12 | 13.0% |
 Cervical cancer | 8 | 8.7% |
 Colorectal cancer | 10 | 10.9% |
 Othersc | 29 | 31.5% |
 NPCd | 4 | 4.3% |
 Duodenal cancer | 3 | 3.2% |
 Endometrial cancer | 3 | 3.2% |
 Esophageal cancer | 3 | 3.2% |
 Gastric cancer | 3 | 3.2% |
 Renal cancer | 2 | 2.2% |
 Pancreatic cancer | 2 | 2.2% |
 Ampullary carcinoma | 2 | 2.2% |
 Bladder Cancer | 2 | 2.2% |
 Ureteral cancer | 1 | 1.1% |
 Renal pelvic carcinoma | 1 | 1.1% |
 Lung cancer | 1 | 1.1% |
 Testicular cancer | 1 | 1.1% |
 Embryo cancer | 1 | 1.1% |